Filtered By:
Drug: Simvastatin

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 124 results found since Jan 2013.

The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial
Conclusion The clinical benefit of adding ezetimibe to statin appears to be enhanced in patients with prior CABG, supporting the use of intensive lipid lowering therapy in these high-risk patients following ACS.
Source: European Heart Journal - January 12, 2017 Category: Cardiology Authors: Eisen, A., Cannon, C. P., Blazing, M. A., Bohula, E. A., Park, J.-G., Murphy, S. A., White, J. A., Giugliano, R. P., Braunwald, E., on behalf of the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators Tags: Acute coronary syndromes Source Type: research

Simvastatin Promotes Hematoma Absorption and Reduces Hydrocephalus Following Intraventricular Hemorrhage in Part by Upregulating CD36
AbstractWe previously found that hematoma worsens hydrocephalus after intraventricular hemorrhage (IVH) via increasing iron deposition and aggravating ependymal cilia injury; therefore, promoting hematoma absorption may be a promising strategy for IVH. Recently, some investigations imply that simvastatin has the ability of accelerating hematoma absorption. Thus, this study was designed to examine the efficacy of simvastatin for IVH in rats. Intracerebral hemorrhage with ventricular extension was induced in adult male Sprague –Dawley rats after autologous blood injection. Simvastatin or vehicle was administered orally at ...
Source: Translational Stroke Research - January 18, 2017 Category: Neurology Source Type: research

Using Lower Cost Statins Improves Outcomes for Normal Cholesterol Non-diabetic Patients.
CONCLUSIONS Under budget constraints, using Simvastatin instead of branded Rosuvastatin resulted in a 47 fold increase of prevention of MACE for the entire IUP. These results should be considered while initiating statin therapy in this target population. PMID: 28277855 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 10, 2017 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Original Articles
Conclusions— Addition of ezetimibe to statin therapy in patients with a recent acute coronary syndrome leads to reductions in cardiovascular-related hospitalizations and associated costs, with the greatest cost offsets in high-risk patients. These cost reductions may completely offset the cost of the drug once ezetimibe becomes generic, and may lead to cost savings from the perspective of the healthcare system, if treatment with ezetimibe is targeted to high-risk patients. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique Identifier: NCT00202878
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2017 Category: Cardiology Authors: Pokharel, Y., Chinnakondepalli, K., Vilain, K., Wang, K., Mark, D. B., Davies, G., Blazing, M. A., Giugliano, R. P., Braunwald, E., Cannon, C. P., Cohen, D. J., Magnuson, E. A. Tags: Secondary Prevention, Cost-Effectiveness, Health Services Original Articles Source Type: research

Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function
Efficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as eGFR declines. The strongest evidence supporting the cardiovascular benefit of statins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo. However, whether combination therapy or statin alone resulted in cardiovascular benefit is uncertain. Therefore, we estimated GFR in 18,015 individuals from the IMPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in individuals with cardiovascular disease and creatinine clearance >30 ml/min) and examined post hoc the relationsh...
Source: Journal of the American Society of Nephrology : JASN - September 29, 2017 Category: Urology & Nephrology Authors: Stanifer, J. W., Charytan, D. M., White, J., Lokhnygina, Y., Cannon, C. P., Roe, M. T., Blazing, M. A. Tags: Clinical Research Source Type: research

Escaping the atherogenic trap: Preventing LDL fusion and binding in the intima
Low-density lipoprotein (LDL) cholesterol plasma concentrations have served as the target of clinical treatment of atherosclerosis-related diseases since the development of simvastatin three decades ago. Targeting endogenous cholesterol synthesis by the inhibition of β-hydroxy-β-methylglutaryl co-enzyme A (HMG-CoA) reductase, statins have since become a mainstay in the lowering of plasma cholesterol and LDL levels and the improvement of cardiovascular outcomes such as myocardial infarction and stroke.
Source: Atherosclerosis - May 18, 2018 Category: Cardiology Authors: Martin Houde, Miranda Van Eck Tags: Editorial Source Type: research

Simvastatin improves cerebrovascular injury caused by ischemia ‑reperfusion through NF‑κB‑mediated apoptosis via MyD88/TRIF signaling.
In conclusion, simvastatin treatment may reduce I/R‑induced neuronal apoptosis via inhibition of the NF‑κB‑mediated MyD88/TRIF signaling pathway. PMID: 30066928 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - August 3, 2018 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Differences in Statin Utilization and Lipid-Lowering by Race, Ethnicity, and HIV Status in a Real-World Cohort of Persons with Human Immunodeficiency Virus and Uninfected Persons
ConclusionsAmong PWH with statin indication(s), Blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin utilized for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - December 21, 2018 Category: Cardiology Source Type: research

Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons
ConclusionsAmong PWH with statin indication(s), blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin used for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - January 25, 2019 Category: Cardiology Source Type: research

Interaction between warfarin and astaxanthin: A case report
This report explains the potential interaction between warfarin and astaxanthin in a 69-year-old Thai woman with history of ischemic stroke. Before taking astaxanthin, the patient used constant doses of warfarin, atenolol, digoxin, aspirin, omeprazole, and simvastatin concomitantly for 17 days without any signs and symptoms of adverse events. One day after astaxanthin was supplemented to her treatment regimen, ecchymosis was found on the right side of her groin and thigh. On the next day, area of ecchymosis was larger. International normalized ratio (INR) values increased from 1.4 to 10.38. Warfarin and astaxanthin were wi...
Source: Journal of Cardiology Cases - February 19, 2019 Category: Cardiology Source Type: research

Apelin-13 Suppresses Neuroinflammation Against Cognitive Deficit in a Streptozotocin-Induced Rat Model of Alzheimer ’s Disease Through Activation of BDNF-TrkB Signaling Pathway
Conclusion The data in this manuscript demonstrates that apelin-13 upregulates BDNF against STZ-induced congnitive impairment by suppressing glial cell activity and inflammatory factors release. This suggests apelin signaling may be a new target in the treatment of AD. Ethics Statement All experimental protocols were carried out according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals approved by the Central South University at XiangYa Animal Care and Use Committee. Author Contributions XqQ and LH conceived the study and contributed to its experimental design. HqL carried out the...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Cardioprotective Activity of Agaricus bisporus Against Isoproterenol- Induced Myocardial Infarction in Laboratory Animals
Conclusion: It can be an outcome that EEAB possessed cardioprotective activity against experimental and clinical studies of ISO-induced myocardial infarction in rats.
Source: Current Nutrition and Food Science - June 28, 2019 Category: Nutrition Source Type: research

Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study
Publication date: Available online 30 August 2019Source: The Lancet Global HealthAuthor(s): John K Lin, Andrew E Moran, Kirsten Bibbins-Domingo, Bode Falase, Andrea Pedroza Tobias, Charuta N Mandke, Dhruv S KaziSummaryBackgroundFewer than 25% of patients with atherosclerotic cardiovascular disease in countries of low and middle income (LMICs) use guideline-directed drugs for secondary prevention. A fixed-dose combination polypill might improve cardiovascular outcomes by increasing prescription rates and adherence, but the cost-effectiveness of this approach is uncertain.MethodsWe developed microsimulation models to assess ...
Source: The Lancet Global Health - September 1, 2019 Category: International Medicine & Public Health Source Type: research

Effect of Simvastatin on Permeability in Cerebral Cavernous Malformation Type 1 Patients: Results from a Pilot Small Randomized Controlled Clinical Trial
Source: Translational Stroke Research - October 22, 2019 Category: Neurology Source Type: research

Simvastatin preconditioning confers neuroprotection against hypoxia-ischemia induced brain damage in neonatal rats via autophagy and silent information regulator 1 (SIRT1) activation.
This study provides further preclinical evidence of the PC-like effect of statins in brain tissue, supporting their beneficial effects in improving stroke outcome after prophylactic treatments. PMID: 31734315 [PubMed - as supplied by publisher]
Source: Experimental Neurology - November 13, 2019 Category: Neurology Authors: Carloni S, Balduini W Tags: Exp Neurol Source Type: research